All Episodes

May 30, 2024 23 mins

This transcript explores the challenges faced by both physicians and patients in accessing treatment.

Professor Vogel discusses the differences in treatment access between Germany and Canada, having experienced both healthcare systems. He highlights the restrictive criteria for liver transplantation in Germany and the limited availability of certain therapies in Canada, particularly for rare cancers like cholangiocarcinoma. The discussion delves into the ethical implications of withholding potentially life-saving treatments and the need for a more streamlined and patient-centered approach to reimbursement. Financial toxicity is also examined, as well as the role of patient advocacy in driving change and ensuring timely access to treatment.

The transcript concludes with a call to action for patients and healthcare professionals to advocate for improved access to the right treatment at the right time.

Mark as Played

Advertise With Us

Popular Podcasts

United States of Kennedy
Dateline NBC

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

Bookmarked by Reese's Book Club

Bookmarked by Reese's Book Club

Welcome to Bookmarked by Reese’s Book Club — the podcast where great stories, bold women, and irresistible conversations collide! Hosted by award-winning journalist Danielle Robay, each week new episodes balance thoughtful literary insight with the fervor of buzzy book trends, pop culture and more. Bookmarked brings together celebrities, tastemakers, influencers and authors from Reese's Book Club and beyond to share stories that transcend the page. Pull up a chair. You’re not just listening — you’re part of the conversation.

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2025 iHeartMedia, Inc.